PMID- 17298424
OWN - NLM
STAT- MEDLINE
DCOM- 20070731
LR  - 20151119
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 62
IP  - 2
DP  - 2007 Feb
TI  - Omalizumab decreases nonspecific airway hyperresponsiveness in vitro.
PG  - 154-61
AB  - BACKGROUND: In asthmatic patients, both symptoms and hyperresponsiveness are 
      related to immunoglobulin E (IgE) concentration in serum. The anti-IgE monoclonal 
      antibody omalizumab improved the control of asthma, but its effect on airway 
      hyperresponsiveness is controversial. Passive sensitization reproduced in vitro a 
      bronchial hyperresponsiveness, an increase in IgE bearing cells, and a mast cell 
      degranulation. This study was designed to examine the effect of omalizumab on 
      passive sensitization-induced hyperresponsiveness, alterations in IgE positive 
      inflammatory cells and mast cell degranulation within the bronchial wall. 
      METHODS: Proximal (3-5 mm diameter) and distal (0.5-1.5 mm diameter) human 
      bronchi dissected out from 10 lung specimens were incubated in normal or 
      asthmatic serum containing various concentrations of omalizumab. Contractile 
      responses to histamine or Dermatophagoides pteronyssinus (D. pter) were recorded 
      using an organ bath system and expressed as percentage of maximal contractile 
      response to acetylcholine (ACh). Immunohistochemistry was performed using 
      monoclonal antibodies directed against IgE or tryptase. Mast cells were 
      classified as fully granulated (type I), partly (type II) or largely degranulated 
      (type III). RESULTS: The specific bronchial hyperresponsiveness to D. pter and 
      the nonspecific bronchial hyperresponsiveness to histamine following passive 
      sensitization were significantly inhibited by omalizumab in both distal and 
      proximal airways. Passive sensitization-induced increase in IgE positive cells 
      was also abolished by omalizumab in a concentration dependent manner. Mast cell 
      degranulation which was inhibited by omalizumab was positively correlated with 
      the contractile response to D. pter. CONCLUSIONS: Omalizumab blocks specific and 
      nonspecific bronchial hyperresponsiveness. Anti-IgE also decreases IgE bearing 
      cell number and mast cell degranulation.
FAU - Berger, P
AU  - Berger P
AD  - Laboratoire de Physiologie Cellulaire Respiratoire, Universite Victor Segalen 
      Bordeaux 2, INSERM E356, Bordeaux, France.
FAU - Scotto-Gomez, E
AU  - Scotto-Gomez E
FAU - Molimard, M
AU  - Molimard M
FAU - Marthan, R
AU  - Marthan R
FAU - Le Gros, V
AU  - Le Gros V
FAU - Tunon-de-Lara, J M
AU  - Tunon-de-Lara JM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/immunology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Bronchial Hyperreactivity/*drug therapy/immunology
MH  - Cell Degranulation/drug effects/immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*immunology
MH  - Immunohistochemistry
MH  - Male
MH  - Mast Cells/immunology
MH  - Middle Aged
MH  - Omalizumab
EDAT- 2007/02/15 09:00
MHDA- 2007/08/01 09:00
CRDT- 2007/02/15 09:00
PHST- 2007/02/15 09:00 [pubmed]
PHST- 2007/08/01 09:00 [medline]
PHST- 2007/02/15 09:00 [entrez]
AID - ALL1243 [pii]
AID - 10.1111/j.1398-9995.2006.01243.x [doi]
PST - ppublish
SO  - Allergy. 2007 Feb;62(2):154-61. doi: 10.1111/j.1398-9995.2006.01243.x.